GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » EV-to-FCF

Lin BioScience (ROCO:6696) EV-to-FCF : -4.02 (As of May. 18, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lin BioScience's Enterprise Value is NT$4,070.79 Mil. Lin BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-1,012.82 Mil. Therefore, Lin BioScience's EV-to-FCF for today is -4.02.

The historical rank and industry rank for Lin BioScience's EV-to-FCF or its related term are showing as below:

ROCO:6696' s EV-to-FCF Range Over the Past 10 Years
Min: -53.03   Med: -20.63   Max: -2.53
Current: -4

During the past 8 years, the highest EV-to-FCF of Lin BioScience was -2.53. The lowest was -53.03. And the median was -20.63.

ROCO:6696's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs ROCO:6696: -4.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Lin BioScience's stock price is NT$92.70. Lin BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-9.290. Therefore, Lin BioScience's PE Ratio for today is At Loss.


Lin BioScience EV-to-FCF Historical Data

The historical data trend for Lin BioScience's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience EV-to-FCF Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -8.04 -32.55 -41.01 -29.87 -6.92

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.01 - -29.87 - -6.92

Competitive Comparison of Lin BioScience's EV-to-FCF

For the Biotechnology subindustry, Lin BioScience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lin BioScience's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Lin BioScience's EV-to-FCF falls into.



Lin BioScience EV-to-FCF Calculation

Lin BioScience's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4070.794/-1012.818
=-4.02

Lin BioScience's current Enterprise Value is NT$4,070.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lin BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-1,012.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lin BioScience  (ROCO:6696) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lin BioScience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=92.70/-9.290
=At Loss

Lin BioScience's share price for today is NT$92.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lin BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-9.290.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Lin BioScience EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Lin BioScience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines